GROUP ONE TRADING, L.P. - NYMOX PHARMACEUTICAL CORP ownership

NYMOX PHARMACEUTICAL CORP's ticker is NYMX and the CUSIP is P73398102. A total of 58 filers reported holding NYMOX PHARMACEUTICAL CORP in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
GROUP ONE TRADING, L.P. ownership history of NYMOX PHARMACEUTICAL CORP
ValueSharesWeighting
Q2 2023$1,008
-43.4%
5,307
+1.3%
0.00%
Q1 2023$1,782
+21.5%
5,240
+6.1%
0.00%
Q4 2022$1,467
-51.1%
4,940
-17.0%
0.00%
Q3 2022$3,000
-93.3%
5,950
-83.5%
0.00%
Q1 2022$45,000
+4400.0%
36,080
+5953.7%
0.00%
Q4 2021$1,000
-97.8%
596
-97.3%
0.00%
Q3 2021$45,000
+650.0%
22,029
+460.4%
0.00%
Q2 2021$6,000
+200.0%
3,931
+281.3%
0.00%
Q1 2021$2,0001,031
+4809.5%
0.00%
Q4 2020$021
-4.5%
0.00%
Q3 2020$0
-100.0%
22
-96.5%
0.00%
Q2 2020$2,000
-84.6%
622
-88.9%
0.00%
Q1 2020$13,000
+333.3%
5,622
+280.6%
0.00%
Q4 2019$3,0001,477
+1818.2%
0.00%
Q3 2019$0
-100.0%
77
-99.2%
0.00%
Q3 2018$25,000
-44.4%
10,207
-23.9%
0.00%
Q2 2018$45,000
-79.3%
13,407
-73.9%
0.00%
-100.0%
Q1 2018$217,000
-26.4%
51,397
-42.5%
0.00%0.0%
Q4 2017$295,000
+16.1%
89,372
+34.2%
0.00%0.0%
Q3 2017$254,000
+206.0%
66,576
+251.8%
0.00%
+100.0%
Q2 2017$83,000
-24.5%
18,927
-37.5%
0.00%0.0%
Q1 2017$110,000
+292.9%
30,263
+263.7%
0.00%
Q2 2016$28,000
+47.4%
8,322
+6.8%
0.00%
Q1 2016$19,000
-86.2%
7,793
-81.4%
0.00%
-100.0%
Q4 2015$138,00041,9450.00%
Other shareholders
NYMOX PHARMACEUTICAL CORP shareholders Q4 2020
NameSharesValueWeighting ↓
First Citizens Financial Corp 35,100$89,0000.08%
Geier Asset Management, Inc. 35,000$91,0000.07%
Patriot Financial Group Insurance Agency, LLC 43,250$107,0000.03%
Willow Creek Wealth Management Inc. 24,224$60,0000.02%
WEBSTER BANK, N. A. 70,000$174,0000.02%
Brown Advisory Securities, LLC 28,000$69,0000.01%
Cubic Asset Management, LLC 11,250$28,0000.01%
Tower Research Capital LLC (TRC) 25,613$64,0000.00%
GOFEN & GLOSSBERG LLC /IL/ 25,000$62,0000.00%
Sterling Investment Advisors, Ltd. 2,500$6,0000.00%
View complete list of NYMOX PHARMACEUTICAL CORP shareholders